-
postdoctoral position at the interface of decision analytic modeling, pharmacoepidemiology and clinical hematology-oncology within the Section of Medical Oncology and Hematology, Department of Internal Medicine
-
, cellular biology and signaling, and mouse models of disease, enhancing our understanding of how the allosteric site influences physiology and disease mechanisms. We plan to utilize drug discovery to identify
-
, families), conduct school-based research, and maintain school relations Excellent statistics skills, including experience with longitudinal data analysis and multi-level modeling Excellent communication
-
for functional neuroimaging such as connectome-based predictive modeling. They will also receive training in the clinical neuroscience of preclinical and early-stage disease and in heterogenous Alzheimer’s and
-
models, evaluation of individualized predictions or estimates for individuals with diverse backgrounds, and promotion of health equity using AI models. The Postdoctoral Associate will be responsible for co
-
cell and molecular biology in human cell models, cancer biology, and genomics. Experience in genomic instability, DNA damage/repair, and mutagenesis is beneficial. Computational experience is highly
-
the cell intrinsic immune machinery and DNA damage and repair processes using in vitro cell models, genetic screens (such as CRISPR and RNA interference), and animal models. We have a strong translational
-
single-cell or spatially resolved genomics methods Testing therapeutic interventions in models of ovarian and cardiovascular aging Designing in vivo lineage-tracing and labeling strategies paired with high
-
models, and blockchain-based privacy-preserving learning. The focus will be blockchain technology and machine learning, and candidates with at least one of the backgrounds are welcomed to apply
-
in immunology and / or cancer biology research and the development of new cancer therapies. Experience with in vivo immunotherapy models, mRNA therapeutics, functional genomics and the use of CRISPR